Published in Cell on November 05, 2015
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med (2016) 4.31
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell (2016) 2.26
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 2.04
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature (2017) 1.50
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet (2016) 1.48
TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat Genet (2017) 1.43
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Res (2016) 1.39
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature (2017) 1.38
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (2017) 1.22
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med (2016) 1.22
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (2017) 1.21
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med (2017) 1.21
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med (2017) 1.17
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med (2017) 1.16
Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) (2016) 0.93
ΔNp63α induces the expression of FAT2 and Slug to promote tumor invasion. Oncotarget (2016) 0.92
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell (2016) 0.89
Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations. Genome Res (2016) 0.88
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell (2016) 0.87
Genomic hallmarks of localized, non-indolent prostate cancer. Nature (2017) 0.87
Mutational Landscape of Aggressive Prostate Tumors in African American Men. Cancer Res (2016) 0.85
Increased global transcription activity as a mechanism of replication stress in cancer. Nat Commun (2016) 0.84
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis (2016) 0.83
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun (2016) 0.83
Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat Genet (2016) 0.82
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. Oncologist (2016) 0.82
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep (2016) 0.81
The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol (2016) 0.81
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell (2017) 0.81
Prostate cancer epigenetics and its clinical implications. Asian J Androl (2016) 0.80
Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology (2016) 0.79
Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res (2016) 0.79
The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. J Cell Biol (2017) 0.79
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget (2016) 0.79
Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. Asian J Androl (2016) 0.79
Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits. Epigenetics Chromatin (2016) 0.79
A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice. Oncotarget (2016) 0.79
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep (2016) 0.78
CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer. Pharmaceuticals (Basel) (2017) 0.78
Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1. Mol Cell Biol (2016) 0.78
Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene (2016) 0.78
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget (2016) 0.77
Tissue-specific tumorigenesis: context matters. Nat Rev Cancer (2017) 0.77
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia (2016) 0.77
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS One (2016) 0.77
Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer. Oncogene (2016) 0.77
TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. F1000Res (2016) 0.77
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clin Epigenetics (2016) 0.77
When Genome Maintenance Goes Badly Awry. Mol Cell (2016) 0.77
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. Oncotarget (2016) 0.77
Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. Br J Cancer (2017) 0.77
lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Mol Ther (2017) 0.77
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (2017) 0.76
The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer (2016) 0.76
Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. Eur Urol (2016) 0.76
Expression of Idh1(R132H) in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis. Cancer Cell (2016) 0.76
The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget (2016) 0.76
Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget (2016) 0.76
Precision medicine for advanced prostate cancer. Curr Opin Urol (2016) 0.76
Molecular subtyping of prostate cancer. Curr Opin Urol (2016) 0.76
Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol (2016) 0.76
Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? Prostate Cancer Prostatic Dis (2017) 0.76
MYC Deregulation in Primary Human Cancers. Genes (Basel) (2017) 0.75
TCGA Expedition: A Data Acquisition and Management System for TCGA Data. PLoS One (2016) 0.75
Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets. Sci Rep (2016) 0.75
Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends Endocrinol Metab (2016) 0.75
A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer. Clin Cancer Res (2016) 0.75
Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene (2016) 0.75
Network diffusion-based analysis of high-throughput data for the detection of differentially enriched modules. Sci Rep (2016) 0.75
Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG. Prostate (2017) 0.75
High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. Oncotarget (2016) 0.75
A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers. Sci Rep (2016) 0.75
Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Lett (2016) 0.75
An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer. Cell Rep (2016) 0.75
Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget (2016) 0.75
Gene Expression Differences in Prostate Cancers between Young and Old Men. PLoS Genet (2016) 0.75
Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study. Br J Cancer (2016) 0.75
NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate (2016) 0.75
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun (2017) 0.75
Amplification of MUC1 in prostate cancer metastasis and CRPC development. Oncotarget (2016) 0.75
Cancer genomics: opportunities for medicinal chemistry? Future Med Chem (2016) 0.75
Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. Clin Cancer Res (2016) 0.75
Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol (2017) 0.75
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discov (2016) 0.75
Next generation mapping reveals novel large genomic rearrangements in prostate cancer. Oncotarget (2017) 0.75
TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene (2016) 0.75
Interplay Between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediate Castration Resistance. Mol Cancer Res (2016) 0.75
Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. Aging (Albany NY) (2016) 0.75
Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. J Steroid Biochem Mol Biol (2016) 0.75
Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression. Oncotarget (2017) 0.75
Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer. Oncotarget (2016) 0.75
Distinct Genomic Alterations in Prostate Tumors from African American Men. EBioMedicine (2015) 0.75
Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate (2016) 0.75
Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection. Oncotarget (2016) 0.75
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. J Clin Invest (2016) 0.75
Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clin Epigenetics (2016) 0.75
Prostate cancer: Kinases and CHIPS sign-off personalization of therapy. Nat Rev Urol (2016) 0.75
Integrating phosphoproteomics into the clinical management of prostate cancer. Clin Transl Med (2017) 0.75
Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. Transl Oncol (2016) 0.75
p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer. Oncogene (2016) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer (2009) 4.45
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
The evolutionary history of lethal metastatic prostate cancer. Nature (2015) 3.59
Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer (2007) 3.57
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 3.13
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
Integrative annotation of variants from 1092 humans: application to cancer genomics. Science (2013) 2.98
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol (2014) 2.86
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol (2010) 2.79
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet (2014) 2.72
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 2.29
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev (2011) 2.24
Tracking the origin of metastatic prostate cancer. Eur Urol (2014) 2.20
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun (2014) 1.90
Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene (2008) 1.88
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol (2015) 1.80
Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res (2008) 1.79
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell (2014) 1.73
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep (2014) 1.68
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov (2014) 1.63
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
A rare truncating BRCA2 variant and genetic susceptibility to upper aerodigestive tract cancer. J Natl Cancer Inst (2015) 1.49
Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet (2015) 1.47
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (2015) 1.44
Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A (2014) 1.38
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol (2015) 1.37
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun (2014) 1.27
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res (2013) 1.26
SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (2014) 1.23
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 1.22
Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res (2011) 1.21
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov (2012) 1.21
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res (2015) 1.18
Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene (2005) 1.18
Gleason grade progression is uncommon. Cancer Res (2013) 1.09
DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics (2013) 1.08
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res (2010) 1.07
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. Genome Med (2013) 1.05
Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer (2004) 1.02
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol (2015) 0.99
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res (2014) 0.97
Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol (2014) 0.93
IDH mutation status in prostate cancer. Oncogene (2011) 0.93
DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene (2014) 0.90
Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation. PLoS One (2011) 0.89
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Landscape of somatic retrotransposition in human cancers. Science (2012) 4.37
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Integrated genomic characterization of oesophageal carcinoma. Nature (2017) 2.76
The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21
Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One (2012) 1.76
Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A (2012) 1.63
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet (2016) 1.16
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 1.06
Integrated genomic and molecular characterization of cervical cancer. Nature (2017) 0.96
Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell (2017) 0.92
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell (2017) 0.81
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell (2017) 0.79
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 0.76
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell (2017) 0.75